Abstract
Although bladder cancer (BC) is a common urological disease, there are deficiencies in current methods used for its detection, hence the research on the identification of non- invasive biomarkers is given a high priority. Alpha satellite DNA is a major human satellite DNA (hASAT), which is important for genome stability and whose aberrant overexpression is a hallmark of many human cancers. Here we identified and quantified its release into the circulation of BC patients, demonstrating its increased copy number with respect to healthy controls.
Absolute quantification of extracellular alpha satellite DNA (ecASAT) repeats was performed by nanoplate-based digital PCR using few microliters of blood plasma from cancer patients as well as from BC negative controls. We found that copy number of ecASAT repeats is significantly higher in blood plasma of BC patients than in healthy controls.
The results suggest that the ec-hASAT copy number variation in human plasma could act as a reliable biomarker for early detection of BC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of the "Luigi Curto" Hospital Facility in Polla, Italy, Director Dr. Luigi Mandia, gave ethical approval on 08 March 2021.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
